Development and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. FDA Rare Disease Center of Excellence
2025 · 1st Quarter (Jan 1 - Mar 31)
OMEROS CORPORATION
Filed by THE PETRIZZO GROUP, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 16, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE PETRIZZO GROUP, INC.
- Client
- OMEROS CORPORATION
- Filing UUID
- 43c82736-70f0-495a-99b3-f2b892c23de8
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Development and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. FDA Rare Disease Center of Excellence
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.